Detection of human MCP-4/CCL13 isoforms by SELDI immunoaffinity capture
2006

Detection of MCP-4/CCL13 Isoforms in Serum

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): Leonardo Rossi, Ramy Moharram, Brian M Martin, Richard L White, Monica C Panelli

Primary Institution: Department of Human Morphology and Applied Biology, University of Pisa

Hypothesis

The study aims to characterize MCP-4/CCL13 isoforms in the serum of RCC patients undergoing high-dose IL-2 immunotherapy.

Conclusion

The study successfully identified two different isoforms of human MCP-4/CCL13 in the peripheral blood for the first time.

Supporting Evidence

  • MCP-4/CCL13 is a major chemoattractant for eosinophils and other immune cells.
  • The study detected two isoforms of MCP-4/CCL13 in serum samples.
  • The isoforms were identified using SELDI-TOF-MS technology.

Takeaway

Researchers found two types of a protein called MCP-4/CCL13 in the blood of patients receiving a specific cancer treatment.

Methodology

The study used SELDI immunoaffinity capture technology to analyze serum samples from patients.

Limitations

The study's assessment of MCP-4/CCL13 isoforms was purely qualitative, and differential quantification between pre and post treatment samples was not consistent.

Participant Demographics

Patients with metastatic renal cell carcinoma (RCC) undergoing high-dose IL-2 treatment.

Digital Object Identifier (DOI)

10.1186/1479-5876-4-5

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication